These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 27572136)
1. Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. Horst J; Frei-Jones M; Deych E; Shannon W; Kharasch ED Pediatr Blood Cancer; 2016 Dec; 63(12):2123-2130. PubMed ID: 27572136 [TBL] [Abstract][Full Text] [Related]
2. Low-Dose Ketamine Infusion for Adjunct Management during Vaso-occlusive Episodes in Adults with Sickle Cell Disease: A Case Series. Palm N; Floroff C; Hassig TB; Boylan A; Kanter J J Pain Palliat Care Pharmacother; 2018 Mar; 32(1):20-26. PubMed ID: 29791238 [TBL] [Abstract][Full Text] [Related]
4. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. van Beers EJ; van Tuijn CF; Nieuwkerk PT; Friederich PW; Vranken JH; Biemond BJ Am J Hematol; 2007 Nov; 82(11):955-60. PubMed ID: 17617790 [TBL] [Abstract][Full Text] [Related]
5. Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease. Goldman RD; Mounstephen W; Kirby-Allen M; Friedman JN Pediatrics; 2013 Dec; 132(6):e1634-41. PubMed ID: 24276838 [TBL] [Abstract][Full Text] [Related]
6. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease. Nobrega R; Sheehy KA; Lippold C; Rice AL; Finkel JC; Quezado ZMN Pediatr Res; 2018 Feb; 83(2):445-454. PubMed ID: 28902183 [TBL] [Abstract][Full Text] [Related]
7. Judging the effectiveness of analgesia for children and adolescents during vaso-occlusive events of sickle cell disease. Beyer JE J Pain Symptom Manage; 2000 Jan; 19(1):63-72. PubMed ID: 10687328 [TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD). Tanabe P; Silva S; Bosworth HB; Crawford R; Paice JA; Richardson LD; Miller CN; Glassberg J Am J Hematol; 2018 Feb; 93(2):159-168. PubMed ID: 29047145 [TBL] [Abstract][Full Text] [Related]
9. Improving the Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department. Kavanagh PL; Sprinz PG; Wolfgang TL; Killius K; Champigny M; Sobota A; Dorfman D; Barry K; Miner R; Moses JM Pediatrics; 2015 Oct; 136(4):e1016-25. PubMed ID: 26391933 [TBL] [Abstract][Full Text] [Related]
10. Pain management in children with sickle cell disease. Stinson J; Naser B Paediatr Drugs; 2003; 5(4):229-41. PubMed ID: 12662119 [TBL] [Abstract][Full Text] [Related]
11. Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease. Sheehy KA; Finkel JC; Darbari DS; Guerrera MF; Quezado ZM Pain Pract; 2015 Nov; 15(8):E90-7. PubMed ID: 26205912 [TBL] [Abstract][Full Text] [Related]
12. Perioperative pharmacokinetics of methadone in adolescents. Sharma A; Tallchief D; Blood J; Kim T; London A; Kharasch ED Anesthesiology; 2011 Dec; 115(6):1153-61. PubMed ID: 22037641 [TBL] [Abstract][Full Text] [Related]
13. Ketamine use for management of vaso-occlusive pain in pediatric sickle cell disease. Harris EM; Vilk E; Donado C; Williams A; Heeney MM; Solodiuk J; Greco C; Archer NM Pediatr Blood Cancer; 2023 May; 70(5):e30254. PubMed ID: 36861789 [TBL] [Abstract][Full Text] [Related]
15. Modulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilation. Smith TP; Schlenz AM; Schatz JC; Maitra R; Sweitzer SM Blood Cells Mol Dis; 2015 Feb; 54(2):155-9. PubMed ID: 25486928 [TBL] [Abstract][Full Text] [Related]
16. Daily home opioid use in adults with sickle cell disease: The PiSCES project. Smith WR; McClish DK; Dahman BA; Levenson JL; Aisiku IP; de A Citero V; Bovbjerg VE; Roberts JD; Penberthy LT; Roseff SD J Opioid Manag; 2015; 11(3):243-53. PubMed ID: 25985809 [TBL] [Abstract][Full Text] [Related]
17. Acute pain in children and adults with sickle cell disease: management in the absence of evidence-based guidelines. Field JJ; Knight-Perry JE; Debaun MR Curr Opin Hematol; 2009 May; 16(3):173-8. PubMed ID: 19295432 [TBL] [Abstract][Full Text] [Related]
18. Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain. Carden MA; Brousseau DC; Ahmad FA; Bennett J; Bhatt S; Bogie A; Brown K; Casper TC; Chapman LL; Chumpitazi CE; Cohen D; Dampier C; Ellison AM; Grasemann H; Hickey RW; Hsu LL; Leibovich S; Powell E; Richards R; Sarnaik S; Weiner DL; Morris CR; Am J Hematol; 2019 Jun; 94(6):689-696. PubMed ID: 30916794 [TBL] [Abstract][Full Text] [Related]
19. Management of vaso-occlusive episodes in the day hospital decreases admissions in children with sickle cell disease. Karkoska K; Appiah-Kubi A; Rocker J; Stoffels G; Aygun B Br J Haematol; 2019 Sep; 186(6):855-860. PubMed ID: 31148158 [TBL] [Abstract][Full Text] [Related]
20. Management of severe chronic pain with methadone in pediatric patients with sickle cell disease. LeBlanc Z; Vance C; Payne J; Zhang J; Hilliard L; Lebensburger JD; Howard TH Pediatr Blood Cancer; 2018 Aug; 65(8):e27084. PubMed ID: 29749702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]